Source: BUSINESS WIRE

Press Release: Pherin Pharmaceuticals : Research and Markets: Premenstrual Dysphoric Disorder (PMDD) - Pipeline Review, H1 2015

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/4xpmlq/premenstrual) has announced the addition of the "Premenstrual Dysphoric Disorder (PMDD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Premenstrual Dysphoric Disorder (PMDD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administ

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Kevin McCarthy's photo - President & CEO of Pherin Pharmaceuticals

President & CEO

Kevin McCarthy

CEO Approval Rating

90/100

Read more